Actinogen Medical
We talked with Dr Steve Gourlay, the CEO of Actinogen Medical (ASX:ACW), about the company’s prospects in Alzheimer’s and depression with its groundbreaking Xanamem drug, its unique mechanism of action and the encouraging clinical data that has been gathered to date.
Actinogen’s Phase IIa study in major depressive disorder (MDD) failed to meet the primary endpoint. However, as Steve argues, the drug does work – the data show clinically and statistically significant benefits in Montgomery–Åsberg Depression Rating Scale (MADRS) depression score improvement after six weeks of treatment with Xanamem. Next year there is potential for a signifcant re-rating if the data in Alzheimer’s is good.
Check our ASX buy/sell tips
